Opinion|Videos|February 19, 2025
Future of BCG in NMIBC
Author(s)Mark D. Tyson, MD, MPH, Gary D. Steinberg, MD
Panelists discuss how it would be preferred that BCG monotherapy not remain the first-line treatment for intermediate-risk and high-risk disease within the next 10 years. It is encouraged that the future of first-line treatment be a noninfectious agent that would be easier to develop and include more data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Given these recent advances and emerging agents, do you think BCG monotherapy will remain the first-line treatment for intermediate-risk and high-risk disease?
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
2
Higher saturated fat intake associated with increased mortality in nonmetastatic prostate cancer
3
NeoBLAST trial tests active surveillance after complete response in MIBC
4
What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed
5